DK1432803T3 - Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas - Google Patents

Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas

Info

Publication number
DK1432803T3
DK1432803T3 DK02777726T DK02777726T DK1432803T3 DK 1432803 T3 DK1432803 T3 DK 1432803T3 DK 02777726 T DK02777726 T DK 02777726T DK 02777726 T DK02777726 T DK 02777726T DK 1432803 T3 DK1432803 T3 DK 1432803T3
Authority
DK
Denmark
Prior art keywords
metabolic
fragments
disorders
human
methods
Prior art date
Application number
DK02777726T
Other languages
English (en)
Inventor
Ilya Chumakov
Oxana Guerassimenko
Original Assignee
Serono Genetics Inst Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Inst Sa filed Critical Serono Genetics Inst Sa
Application granted granted Critical
Publication of DK1432803T3 publication Critical patent/DK1432803T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02777726T 2001-10-05 2002-10-03 Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas DK1432803T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32772501P 2001-10-05 2001-10-05
PCT/IB2002/004598 WO2003050281A2 (en) 2001-10-05 2002-10-03 Fragments of the human zn-alpha2-glycolprotein and their use in methods of treatment of obesity

Publications (1)

Publication Number Publication Date
DK1432803T3 true DK1432803T3 (da) 2008-03-10

Family

ID=23277766

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02777726T DK1432803T3 (da) 2001-10-05 2002-10-03 Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas

Country Status (11)

Country Link
US (1) US7402393B2 (da)
EP (1) EP1432803B1 (da)
JP (1) JP4423038B2 (da)
AT (1) ATE380868T1 (da)
AU (1) AU2002339678B2 (da)
CA (1) CA2461491A1 (da)
DE (1) DE60224064T2 (da)
DK (1) DK1432803T3 (da)
ES (1) ES2295415T3 (da)
IL (2) IL161233A0 (da)
WO (1) WO2003050281A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE478890T1 (de) 2002-05-31 2010-09-15 Serono Genetics Inst Sa Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon
AU2003299378A1 (en) * 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
EP1548445A3 (en) * 2003-12-22 2005-11-23 F. Hoffmann-La Roche Ag Novel targets for obesity from fat tissue
US20100173829A1 (en) * 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
CA2878695A1 (en) * 2012-07-25 2014-01-30 University Of Cincinnati Method of treating type i diabetes using apolipoprotein aiv
KR102149202B1 (ko) * 2017-09-29 2020-08-28 주식회사 엘앤씨바이오 Zag 유래 펩타이드 및 그의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9811465D0 (en) 1998-05-29 1998-07-29 Tisdale Michael J Glycoproteins having lipid mobilising properties and therapeutic applications thereof
AU785090B2 (en) 2000-01-14 2006-09-14 Serono Genetics Institute S.A. OBG3 globular head and uses thereof for decreasing body mass
US20050065079A1 (en) * 2001-10-12 2005-03-24 Aaron Scalia Ngzipa,ngzipd,pgzipa and pgzipd polynucleotides and polypeptides and uses thereof

Also Published As

Publication number Publication date
WO2003050281A3 (en) 2003-12-04
WO2003050281A2 (en) 2003-06-19
AU2002339678B2 (en) 2007-10-25
IL161233A0 (en) 2004-09-27
ATE380868T1 (de) 2007-12-15
US7402393B2 (en) 2008-07-22
ES2295415T3 (es) 2008-04-16
DE60224064D1 (de) 2008-01-24
EP1432803A2 (en) 2004-06-30
JP2005511088A (ja) 2005-04-28
AU2002339678B8 (en) 2003-06-23
US20070054845A1 (en) 2007-03-08
EP1432803B1 (en) 2007-12-12
IL161233A (en) 2010-05-17
CA2461491A1 (en) 2003-06-19
AU2002339678A1 (en) 2003-06-23
DE60224064T2 (de) 2008-11-20
JP4423038B2 (ja) 2010-03-03

Similar Documents

Publication Publication Date Title
ATE405655T1 (de) Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
NO20056049L (no) Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20055741L (no) Nye kjemiske forbindelser
ATE424416T1 (de) Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
WO2005046583A3 (en) Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
DK1432803T3 (da) Fragmenter af det humane ZN alfa2 glycoprotein og deres anvendelse ved fremgangsmåder til behandling af obesitas
IS6894A (is) Aðferðir til þess að meðhöndla og koma í veg fyrir húðraskanir með því að hota hrifefni sem binda
DE60223037D1 (de) Chitin-mikropartikel und ihre medizinische verwendung
ATE304854T1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
WO2006039638A3 (en) Treating renal cell carcinoma with an anti-tnf human antibody or fragment
MXPA05009193A (es) Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.
ATE480232T1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
WO2003033534A3 (en) Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof
ATE472332T1 (de) Zusammensetzung mit notoginseng radix extrakt zur prävention und behandlung von arthritis als wirksamer inhaltsstoff
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
WO2003082915A3 (en) Xcrf polynucleotides and polypeptides and uses thereof
WO2002055694A3 (en) Discriminative nucleic acid analysis using clone sequence signatures
FR2837495B1 (fr) Installation modulable, demontable, transportable, pour le traitement par thermolyse et pour la valorisation energetique des dechets
WO2002060466A3 (en) Gssp3 polynucleotides and polypeptides and uses thereof
DE60228408D1 (de) Gssp4-polynukleotide und -polypeptide sowie deren verwendung